| Dr Victoria M Foley, DPM | |
|
3747 Worsham Ave, Suite 201, Long Beach, CA 90808-1774 | |
| (562) 420-9800 | |
| (562) 420-9884 |
| Full Name | Dr Victoria M Foley |
|---|---|
| Gender | Female |
| Speciality | Podiatry |
| Experience | 34 Years |
| Location | 3747 Worsham Ave, Long Beach, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295704864 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | E3774 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Long Beach Memorial Medical Center | Long beach, CA | Hospital |
| Los Alamitos Medical Center | Los alamitos, CA | Hospital |
| Provider Name | Victoria Foley Podiatric Medical |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1760679583 PECOS PAC ID: 9638381387 Enrollment ID: O20121101000250 |
News Archive
Scientists at Dana-Farber Cancer Institute have identified natural human antibodies against the virus that causes Middle East Respiratory Syndrome (MERS), a step toward developing treatments for the newly emerging and often-fatal disease.
The use of an oral anticoagulant medicine in medically ill patients for 45 days following their discharge from the hospital reduces the rate of non-fatal symptomatic blood clots with no impact on fatal blood clots, according to late breaking results from the MARINER trial presented today in a Hot Line Session at ESC Congress 2018 and published in The New England Journal of Medicine.
PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.
Liver cancer (Hepatocellular Carcinoma, HCC) usually arises as the result of a chronic, inflammatory liver disease. The most common causes here are excessive alcohol consumption as well as a high-fat diet and also chronic infection with the hepatitis viruses B and C. In the course of the inflammatory process, the liver cells (hepatocytes) die more frequently due to programmed cell death.
Some patients with metastatic renal cell carcinoma who are switched from a traditional sunitinib treatment schedule to an alternative schedule fare better on survival measures and suffer fewer adverse events, a Japanese study has found.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Victoria M Foley, DPM 3747 Worsham Ave, Suite 201, Long Beach, CA 90808-1774 Ph: (562) 420-9800 | Dr Victoria M Foley, DPM 3747 Worsham Ave, Suite 201, Long Beach, CA 90808-1774 Ph: (562) 420-9800 |
News Archive
Scientists at Dana-Farber Cancer Institute have identified natural human antibodies against the virus that causes Middle East Respiratory Syndrome (MERS), a step toward developing treatments for the newly emerging and often-fatal disease.
The use of an oral anticoagulant medicine in medically ill patients for 45 days following their discharge from the hospital reduces the rate of non-fatal symptomatic blood clots with no impact on fatal blood clots, according to late breaking results from the MARINER trial presented today in a Hot Line Session at ESC Congress 2018 and published in The New England Journal of Medicine.
PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.
Liver cancer (Hepatocellular Carcinoma, HCC) usually arises as the result of a chronic, inflammatory liver disease. The most common causes here are excessive alcohol consumption as well as a high-fat diet and also chronic infection with the hepatitis viruses B and C. In the course of the inflammatory process, the liver cells (hepatocytes) die more frequently due to programmed cell death.
Some patients with metastatic renal cell carcinoma who are switched from a traditional sunitinib treatment schedule to an alternative schedule fare better on survival measures and suffer fewer adverse events, a Japanese study has found.
› Verified 3 days ago
Ben Buchholtz, M.D. Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 4100 Long Beach Blvd, #200, Long Beach, CA 90807 Phone: 562-426-0396 Fax: 562-426-7551 | |
Joseph Paul Oehmen, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 2801 Atlantic Ave, Long Beach, CA 90806 Phone: 562-933-3806 | |
Mr. Ki Sang Yi, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1703 Termino Ave, Suite #103, Long Beach, CA 90804 Phone: 562-597-5100 Fax: 562-597-5165 | |
Dr. Marjorie J Khawam, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 3816 Woodruff Ave, Ste 302, Long Beach, CA 90808 Phone: 562-429-5300 Fax: 562-429-0535 | |
Dr. Raymond M Bautista, Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 701 E 28th St, Suite 111, Long Beach, CA 90806 Phone: 562-426-2551 Fax: 562-988-0610 | |
Richard L Bell Dpm Inc Podiatrist Medicare: Medicare Enrolled Practice Location: 1760 Termino Ave, 309, Long Beach, CA 90804 Phone: 562-986-9911 Fax: 562-986-6885 | |
Dr. Dennis R. Gumm, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 4508a Atlantic Ave, # A138, Long Beach, CA 90807 Phone: 310-378-5424 |